Suchergebnisse - "9NDF7JZ4M3"

PubPharm (39)

1

Learning with COVID-19 : what about anticoagulation?

enthalten in: Anales del sistema sanitario de Navarra | 2020

von Álvarez-Rodríguez, E. | González González, R. | Torres-Gárate, R. | +3

CommentIn: An Sist Sanit Navar. 2021 Apr 28;44(1):127-128. - PMID 33853211

2

Management of bleeding associated with direct oral anticoagulants : update on reversal strategies

enthalten in: Revista medica de Chile | 2019

von Enríquez, A. | Baranchuk, A. | Corbalán, R.

3

Oral anticoagulation in atrial fibrillation : What is the guideline for using new drugs?

enthalten in: Semergen | 2018

von Ibáñez Pérez de Viñaspre, J. | Gómez Bitrian, J. | Royo Hernández, R. | +3

4

Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study

enthalten in: Atencion primaria | 2018

von de la Figuera, M. | Cinza, S. | Marín, N. | +3

5

Pruritus and rivaroxaban

enthalten in: Semergen | 2018

von Aguilar-Shea, A. | Gallardo-Mayo, C.

6

Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report

enthalten in: Revista medica de Chile | 2017

von Rivera O, G. | Corsi S, O. | Pavlovic J, A. | +2

7

From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation

enthalten in: Semergen | 2017

von Barrios, V. | Escobar, C.

8

Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain

enthalten in: Revista de neurologia | 2017

von Monreal-Bosch, M. | Soulard, S. | Crespo, C. | +2

9

Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation

enthalten in: Revista medica de Chile | 2016

von Neira, V. | Corbalán, R. | Pereira, J. | +5

10

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes : A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)

enthalten in: Semergen | 2016

von Divisón Garrote, J. | Escobar Cervantes, C.